Sensei Biotherapeutics Inc (SNSE) concluded trading on Wednesday at a closing price of $0.53, with 9.55 million shares of worth about $5.06 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -17.70% during that period and on January 08, 2025 the price saw a gain of about 2.51%. Currently the company’s common shares owned by public are about 25.15M shares, out of which, 16.54M shares are available for trading.
Stock saw a price change of 8.14% in past 5 days and over the past one month there was a price change of 14.97%. Year-to-date (YTD), SNSE shares are showing a performance of 8.14% which decreased to -30.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.38 but also hit the highest price of $1.94 during that period. The average intraday trading volume for Sensei Biotherapeutics Inc shares is 483.16K. The stock is currently trading 12.14% above its 20-day simple moving average (SMA20), while that difference is up 5.92% for SMA50 and it goes to -26.19% lower than SMA200.
Sensei Biotherapeutics Inc (NASDAQ: SNSE) currently have 25.15M outstanding shares and institutions hold larger chunk of about 8.84% of that.
The stock has a current market capitalization of $13.33M and its 3Y-monthly beta is at 0.16. It has posted earnings per share of -$1.19 in the same period. It has Quick Ratio of 8.84 while making debt-to-equity ratio of 0.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SNSE, volatility over the week remained 10.07% while standing at 9.78% over the month.
Stock’s fiscal year EPS is expected to rise by 4.10% while it is estimated to increase by 25.36% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stephens on May 14, 2024 offering an Overweight rating for the stock and assigned a target price of $5 to it. Coverage by Berenberg stated Sensei Biotherapeutics Inc (SNSE) stock as a Hold in their note to investors on July 01, 2021, suggesting a price target of $12 for the stock. On June 29, 2021, Oppenheimer Downgrade their recommendations, while on March 01, 2021, Piper Sandler Initiated their ratings for the stock with a price target of $25. Stock get an Outperform rating from Oppenheimer on March 01, 2021.
